Armune BioScience Announces Agreement Retaining EMA Partners as Advisor and Investment Bank

KALAMAZOO, MICH. March 1, 2017 – Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available in the world to assess the risk for the presence of prostate cancer, announced today that the company has entered into a definitive agreement with EMA Partners (Denver, CO) retaining them as the company’s advisor and investment bank.

In April of 2015, Armune BioScience launched APIFINY to primary care clinicians and urologists in the United States. In less than two years on the market, clinicians have ordered over 10,000 APIFINY tests and the company is preparing to expand commercial operations in the US and several worldwide markets.

“We are very pleased to announce that Armune BioScience has reached an agreement to have EMA Partners serve as our advisor and investment bank. EMA Partners and its elite group of partners and life-science advisors have a remarkable track record of helping to create shareholder value in promising life-science companies,” said David Esposito, President and Chief Executive Officer of Armune BioScience. “After successfully launching APIFINY, we are prepared to scale our commercial operations in the United States and beyond. In addition, we are in final preparations to launch several new products this year based on our proprietary autoantibody technology. We look forward to EMA Partners helping us realize the full potential of our business.”

“EMA Partners looks forward to working with the seasoned management team and board at Armune BioScience as we help them to explore their options to scale the business and develop strategic partnerships with diagnostic and pharmaceutical companies,” said Andy Raeder, founding partner of EMA Partners. “We believe Armune’s autoantibody technology has the potential to significantly improve cancer detection and enhance the outcomes of a broad range of cancer therapies.”

About Armune BioScience
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. Armune was incorporated as a Delaware Corporation in 2008 with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI. For more information, visit

About EMA Partners, LLC
EMA is focused on assisting its clients with mergers, acquisitions, divestitures, intellectual property licensing and sales, recapitalizations, transition planning and other transactional-based services.

The firm applies a process and perspective well suited to middle market clients across all geographies. With a professional staff of advisors from a variety of business disciplines, the firm is able to provide the strategy, analytics, marketing and transactional work to meet clients’ goals across industry verticals. This expertise is reflected in the wide range of transactions EMA has handled, ranging from outright sale of traditional industrial companies to licensing of sophisticated pre-revenue intellectual property.

EMA’s focus has always been on the middle market, and on understanding client companies’ objectives and strengths, communicating those strengths to prospective buyers or partners, and structuring transactions in a manner that maximizes value for our clients.

For more information, visit Securities offered through Burch & Company, Inc., member FINRA/SIPC.